Ticlopidine HydrochlorideA platelet aggregation inhibitor

Ticlopidine Hydrochloride (CAS 53885-35-1)

Ticlopidine Hydrochloride | CAS 53885-35-1 is rated 5.0 out of 5 by 1.
  • y_2019, m_9, d_22, h_20
  • bvseo_bulk, prod_bvrr, vn_bulk_2.0.13
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_205861, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getAggregateRating, 83ms
  • REVIEWS, PRODUCT
Application: A platelet aggregation inhibitor
CAS Number: 53885-35-1
Purity: ≥99%
Molecular Weight: 300.25
Molecular Formula: C14H14ClNS•HCl
* Refer to Certificate of Analysis for lot specific data (including water content).
Submit a review for this product and receive 15 CruzCredits

Ticlopidine hydrochloride is a platelet aggregation inhibitor capable of inducing apoptosis in various cancer cell lines by antagonizing the P2Y12 receptor, which is responsible for initiating the signal transduction that causes platelets to aggregate.


References

Chen WH, Yin HL, Chang YY et al. Kaohsiung J Med Sci. 13:589-97 (1997). Ma L, Elliott SN, Cirino G et al. Proc Natl Acad Sci U S A. 98:6470-5 (2001).

Physical State :
Solid
Solubility :
Soluble in methanol, water (4 mg/ml at 25° C), ethanol (1 mg/ml at 25° C), and DMSO (1 mg/ml at 25° C).
Storage :
Store at 4° C
Melting Point :
190° C
Boiling Point :
367.3° C at 760 mmHg (Predicted)
Refractive Index :
n20D 1.64 (Predicted)
IC50 :
P2 receptor: IC50 = ~2 µM; human platelet aggregation: IC50 = 1057 µM
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
WGK Germany :
3
RTECS :
XJ9089100
PubChem CID :
65335
MDL Number :
MFCD00079606
EC Number :
258-837-4
SMILES :
C1CN(CC2=C1SC=C2)CC3=CC=CC=C3Cl.Cl

Download SDS (MSDS)

Certificate of Analysis

Adobe Acrobat Reader is required to reliably view,
print and comment on PDF documents

Ticlopidine Hydrochloride  Product Citations

See how others have used Ticlopidine Hydrochloride. Click on the entry to view the PubMed entry .

Citations 1 to 1 of 1 total

PMID: # 25422175  Wang, W. et al. 2015. Chirality. 27: 170-6.

Citations 1 to 1 of 1 total
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getContent, 59ms
  • QUESTIONS, PRODUCT
  • bvseo-msg: The resource to the URL or file is currently unavailable.;
Rated 5 out of 5 by from Park MS; et al Park MS; et al. (PubMed ID: 26327247) determined that Ticlopidine Hydrochloride blocks the effect of angiogenic vascular endothelial growth factor by reducing the human umbilical vein endothelial cells, in frog embryos. -SCBT Publication Review
Date published: 2015-01-10
  • y_2019, m_9, d_22, h_20
  • bvseo_bulk, prod_bvrr, vn_bulk_2.0.13
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_205861, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getReviews, 4ms
  • REVIEWS, PRODUCT

Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2019 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.